Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. (SUPN) filed a Current Report on Form 8-K on April 13, 2022. The filing announces the submission of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and provides financial results for the fourth quarter and full year of 2021.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced Form 10-K and the press release furnished as Exhibit 99.1, which are not included in the provided text.
Material Changes
The filing does not detail specific material changes or comparative financial data versus prior periods. It serves as a notification that the annual results have been filed and that the company is reiterating its previously announced financial guidance for fiscal year 2022.
Guidance, Outlook, and Risks
- Guidance: Management reiterated its previously announced financial guidance for fiscal year 2022.
- Forward-Looking Statements: The report contains forward-looking statements regarding plans, strategies, and intentions, subject to risks and uncertainties.
- Risks: Investors are directed to Item 1A, "Risk Factors," in the Form 10-K for the fiscal year ended December 31, 2021, for a detailed discussion of risks, including ordinary business operations and general economic conditions.
Investor Verification Checklist
- Review the full Form 10-K filed on April 13, 2022, for specific revenue, net income, and cash flow figures.
- Examine Exhibit 99.1 (Press Release) for detailed fourth-quarter and full-year 2021 performance metrics.
- Verify the specific details of the reiterated 2022 financial guidance in the referenced press release.
- Consult the "Risk Factors" section of the 2021 Form 10-K for updated disclosures on regulatory, competitive, and operational risks.